2 HIV drugs from Gilead's Stribild fail to win FDA approval as standalones

04/30/2013 | MedCityNews.com

The FDA turned down Gilead Sciences' regulatory applications for elvitegravir and cobicistat as standalone treatments for HIV, citing problems in certain quality testing procedures. The two drugs are included in Gilead's 4-in-1 HIV pill Stribild, which was approved by the FDA last year. Gilead says it is working with the agency to address the issues mentioned in the rejection letter.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA